Westpac Banking Corp Has $240,000 Stake in IQVIA Holdings Inc. $IQV

Westpac Banking Corp grew its position in IQVIA Holdings Inc. (NYSE:IQV) by 64.3% during the second quarter, HoldingsChannel.com reports. The firm owned 1,521 shares of the medical research company’s stock after buying an additional 595 shares during the quarter. Westpac Banking Corp’s holdings in IQVIA were worth $240,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Cetera Investment Advisers raised its position in IQVIA by 37.7% in the 2nd quarter. Cetera Investment Advisers now owns 100,093 shares of the medical research company’s stock valued at $15,774,000 after buying an additional 27,412 shares during the last quarter. Creative Planning raised its holdings in shares of IQVIA by 25.9% in the second quarter. Creative Planning now owns 39,151 shares of the medical research company’s stock valued at $6,170,000 after purchasing an additional 8,051 shares during the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS raised its holdings in shares of IQVIA by 5.4% in the second quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 40,308 shares of the medical research company’s stock valued at $6,352,000 after purchasing an additional 2,050 shares during the last quarter. Allianz SE lifted its position in shares of IQVIA by 213.9% in the second quarter. Allianz SE now owns 3,390 shares of the medical research company’s stock worth $534,000 after purchasing an additional 2,310 shares in the last quarter. Finally, Smithfield Trust Co boosted its holdings in IQVIA by 18.5% during the second quarter. Smithfield Trust Co now owns 691 shares of the medical research company’s stock worth $109,000 after purchasing an additional 108 shares during the last quarter. 89.62% of the stock is currently owned by institutional investors.

Insider Transactions at IQVIA

In other IQVIA news, insider Eric Sherbet sold 4,000 shares of the company’s stock in a transaction on Wednesday, October 29th. The stock was sold at an average price of $219.70, for a total value of $878,800.00. Following the transaction, the insider directly owned 27,108 shares of the company’s stock, valued at $5,955,627.60. This represents a 12.86% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. 1.60% of the stock is owned by company insiders.

IQVIA Stock Down 2.0%

IQV stock opened at $216.24 on Tuesday. The firm has a market capitalization of $36.82 billion, a PE ratio of 29.66, a PEG ratio of 2.48 and a beta of 1.34. The business’s 50 day simple moving average is $203.29 and its 200 day simple moving average is $179.34. IQVIA Holdings Inc. has a 1-year low of $134.65 and a 1-year high of $228.12. The company has a current ratio of 0.70, a quick ratio of 0.70 and a debt-to-equity ratio of 2.03.

IQVIA (NYSE:IQV) last posted its earnings results on Tuesday, October 28th. The medical research company reported $3.00 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.98 by $0.02. The company had revenue of $4.10 billion during the quarter, compared to analysts’ expectations of $4.07 billion. IQVIA had a net margin of 8.07% and a return on equity of 30.70%. IQVIA’s quarterly revenue was up 5.2% compared to the same quarter last year. During the same quarter last year, the company posted $2.84 EPS. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. As a group, research analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Wall Street Analysts Forecast Growth

IQV has been the topic of several analyst reports. William Blair reissued an “outperform” rating on shares of IQVIA in a research report on Wednesday, July 23rd. Redburn Partners set a $214.00 target price on IQVIA in a report on Wednesday, September 3rd. UBS Group increased their price target on IQVIA from $225.00 to $250.00 and gave the company a “buy” rating in a research report on Wednesday, October 29th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of IQVIA in a research report on Wednesday, October 8th. Finally, Barclays increased their price objective on IQVIA from $185.00 to $200.00 and gave the company an “equal weight” rating in a report on Thursday, October 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $241.00.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.